NEW YORK, Feb. 24, 2021 (GLOBE NEWSWIRE) Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline for investors to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE) from May 11, 2020 through November 4, 2020(the “Class Period”). The lawsuit filed in the United States District Court for the Eastern District of New York alleges violations of the Securities Exchange Act of 1934. If you purchased bluebird securities, and/or would like to discuss your legal rights and options please visit BLUE Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com The complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to
Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 19, 2021 to file lead plaintiff applications in a securities class action lawsuit against EHang Holdings Limited (NasdaqGM: EH), if they purchased the Company’s American depositary shares ("ADS") between December 12, 2019 and February 16, 2021 (and on February 16, 2021, only for those who purchased shares at or above the price of $112.00), inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.
NEW YORK, NY / ACCESSWIRE / February 20, 2021 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of FuboTV, Inc. ("Fubo" or the "Company") (NYSE:FUBO) from March 23, 2020 through January 4, 2021 (the "Class Period").
Clover Health Investments, Corp. (CLOV) Securities Class Action:
The Complaint alleges that, throughout the Class Period, Defendants misrepresented and concealed that: (1) Clover s Clover Assistant platform was under investigation by the Department of Justice for at least 12 issues ranging from kickbacks to marketing practices to undisclosed third-party deals; (2) the DOJ s investigation presented an existential risk to Clover because it derives most of its revenues from Medicare; and (3) Clover s sales were driven by a major undisclosed related party deal and misleading marketing targeting the elderly, not its purported best-in-class technology.
Investors allegedly began to learn the truth on Feb. 4, 2021 when Hindenburg Research released a scathing report about the company, alleging Clover s sales are the product of misleading marketing activities targeting the elderly and a major undisclosed related party deal.